創新生物藥開發與先進技術製造法規指導原則制訂觀點分享
Regulatory Guidelines for Innovative Biopharmaceuticals and Advanced Manufacturing: Perspectives and Insights
訊聯生技蔡政憲董事長受邀出席「財團法人醫藥品查驗中心 - 創新生物藥開發與先進技術製造法規指導原則制訂觀點分享」系列活動，
並於現場針對「外泌體於再生醫療與精準治療之發展趨勢經驗分享」進行交流。
因應新興生物藥品疾病治療需求增加，近年以生技藥品、細胞/外泌體製劑等創新生物產品發展迅速。
訊聯細胞智藥專攻外泌體及細胞治療新藥開發，像是外泌體Exosome新藥治療乾眼症，已獲得階段性的研究成果，未來可望造福廣大有需求的族群。
BIONET Corp.'s Chairman, Chih-Hsien Tsai, was invited to participate in the "Innovative Biopharmaceutical Development and Advanced Technology Manufacturing Regulatory Guidelines" series hosted by the Foundation for Medical Inspection Center.
During the event, he shared insights on the "Advancements and Experiences in Exosome Applications for Regenerative Medicine and Precision Therapy."
With the growing demand for novel biopharmaceuticals in disease treatment, there has been significant progress in the development of innovative biological products, including biologics, cells, and exosome preparations.
BIONET Therapeutics Corp. specializes in the development of exosome and cell-based therapies. For instance, our exosome-based therapy for dry eye syndrome has yielded promising preliminary research outcomes, poised to benefit diverse populations in need in the future.
